{"id":"r-mnhl-bfm-90-auto-sct","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL3663397","moleculeType":"Small molecule","molecularWeight":"414.51"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This is a multimodal approach combining rituximab (anti-CD20 monoclonal antibody) with the BFM-90 chemotherapy backbone (typically including cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by autologous stem cell transplantation (auto-SCT). The rituximab targets CD20 antigen on malignant B cells, while the chemotherapy provides cytotoxic effects, and auto-SCT allows delivery of higher chemotherapy doses with hematopoietic recovery.","oneSentence":"R-mNHL-BFM-90 is a rituximab-based chemotherapy regimen combined with autologous stem cell transplantation to treat non-Hodgkin lymphoma by targeting CD20+ B cells and providing high-dose chemotherapy with stem cell rescue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:08.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory non-Hodgkin lymphoma (B-cell)"}]},"trialDetails":[{"nctId":"NCT02842931","phase":"PHASE3","title":"R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2015-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-mNHL-BFM-90 + auto-SCT","genericName":"R-mNHL-BFM-90 + auto-SCT","companyName":"National Research Center for Hematology, Russia","companyId":"national-research-center-for-hematology-russia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-mNHL-BFM-90 is a rituximab-based chemotherapy regimen combined with autologous stem cell transplantation to treat non-Hodgkin lymphoma by targeting CD20+ B cells and providing high-dose chemotherapy with stem cell rescue. Used for Relapsed or refractory non-Hodgkin lymphoma (B-cell).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}